FDA approves Benlysta for children with lupus nephritis, first biologic for this condition.

The FDA has approved Benlysta, an autoinjector for subcutaneous injection, for patients aged 5 and older with active lupus nephritis. It's the first approved biologic for both systemic lupus erythematosus and lupus nephritis. Common adverse reactions include serious infections, nausea, diarrhea, fever, throat inflammation, bronchitis, insomnia, pain, depression, migraine, and injection site reactions.